Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Tryp Therapeutics (TRYP) began enrolling patients for a Phase 2 trial on psilocybin for binge eating. The company is using non-proprietary synthetic psilocybin to generate data quickly while developing a proprietary formulation.

PDF of article

The cure for constant hunger

TRYP THERAPEUTICS SUBMITS IND APPLICATION FOR PHASE 2A CLINICAL TRIAL IN EATING DISORDERS

Can shrooms treat this rare genetic disorder?

Tryp Therapeutics (TRYP) is preparing for a Phase 2a study on overeating disorders including a rare condition called Prader-Willi Syndrome, a genetic disorder that causes intellectual disability, shortness in height, and constant hunger than often leads to obesity and diabetes.

The clinical trial is expected to begin in Q4 of this year and will investigate various other eating disorders such as binge eating and hypothalamic obesity. Ten patients will be given two doses of psilocybin, which in theory will increase neuroplasticity to create healthier neural patterns related to eating habits.

The San Diego company just filed a Investigational New Drug (IND) application with the FDA, for TRP-8802, the psilocybin formulation that will be used in the study.

PDF of article

Tryp Therapeutics (TRYP) aims to use psychedelics in eating disorder treatment

Dr. Jennifer Miller | Principal Investigator, Tryp Therapeutics

Tryp Therapeutics Inc. (TRYP), is conducting a phase 2 clinical trial that will investigate psilocybin’s effect on hypothalamic obesity conditions. Principal Investigator Dr. Jennifer Miller is confident that psilocybin therapy will reduce appetite drive, food-related anxiety, compulsive eating, and impulsive eating by rewiring neural pathways to alleviate the underlying psychiatric issues. She is hopeful that psilocybin could treat millions of patients with a wide range of previously untreatable, chronic conditions.

PDF of article